SD Express Delivers New Gigabyte Speeds for SD Memory Cards
The SD Association announced today the SD 8.0 Specification for SD Express memory cards receives even faster transfer speeds by using the popular PCI Express® (PCIe®) 4.0 specification delivering a maximum of nearly 4 gigabytes per second (GB/s) data transfer rate. These full sized cards continue to use the NVMe Express™ (NVMe™) upper layer protocol enabling advanced memory access mechanism. As always SD Express memory cards using SD 8.0 specification maintain backward compatibility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005027/en/
SD Express memory card types (Photo: Business Wire)
“SD Express’ use of even faster PCIe and NVMe architectures to deliver faster transfer speeds creates more opportunities for devices to use SD memory cards,” said Mats Larsson, Senior Market Analyst at Futuresource. “This combination of trusted and well-known technologies makes it easier for future product designs to leverage the benefits of removable storage in new ways.”
SD Express gigabyte speeds bring new storage opportunities for devices with demanding performance levels, across a variety of industries. The cards can move large amounts of data generated by data-intense wireless or wired communication, super-slow motion video, RAW continuous burst mode and 8K video capture and playback, 360 degree cameras/videos, speed hungry applications running on cards and mobile computing devices, ever evolving gaming systems, multi-channel IoT devices and automotive to name a few. SD Express will be offered on SDHC, SDXC and SDUC memory cards.
“By dramatically increasing the speeds for SD Express we’re giving device manufacturers and system developers more storage choices,” said Hiroyuki Sakamoto, SDA president. “SD 8.0 may open even more opportunities for extra high performance solutions using removable memory cards.”
“PCI-SIG® is pleased to see that SDA is continuing to adopt even faster PCIe technology configurations using PCIe 4.0 interface and dual lanes for one of the top leading removable memory cards – SD,” said Al Yanes, PCI-SIG president and chairman. “PCIe specification conformance tests are available today by major test vendors, offering a significant advantage for any new PCIe technology adopter.”
“NVMe is the industry-recognized performance SSD interface from the client to the datacenter, shipping in millions of units,” said Amber Huffman, NVM Express™ Inc. president. “Consumers will benefit by SD Association continuing the adoption of the NVMe base specification for their latest SD Express cards.”
SD Express uses the well-known PCIe 4.0 specification and the latest NVMe specification (up to version 1.4) defined by PCI-SIG and NVM Express, respectively. SD 8.0 specification provides two transfer speed options for SD Express memory cards. The two transfer speeds are accomplished by supporting either PCIe 3.0 x2 or PCIe 4.0 x1 architectures with up to ~2GB/s and with PCIe 4.0 x2 technology with up to 4GB/s. SD Express cards offering PCIe 4.0 x1 architecture use the same form factor as defined for SD 7.0 specification cards with a second row of pins to deliver transfer speeds up to 2 GB/s. SD Express cards supporting dual PCIe lanes (PCIe 3.0 x2 or PCIe 4.0 x2 technologies) have three rows of pins.
The SDA makes adoption of SD Express easy allowing companies to use existing test equipment and saving in product development costs. The SD 8.0 specification continues giving system developers access to PCIe and NVMe technologies, such as Bus Mastering, Multi Queue (without locking mechanism) and Host Memory Buffer.
Two revised white papers, “SD Express Cards with PCIe and NVMe Interfaces,” and “SD Express and microSD Express Memory Cards: The Best Choice for Your Future Product Designs” provide an in-depth look at the opportunities created by SD Express. More information is available on our website.
Visit the SDA Virtual Tradeshow to learn more about SD Express solutions offered by our members.
The SD Association is a global ecosystem of nearly 900 technology companies charged with setting interoperable SD standards. The Association encourages the development of consumer electronic, wireless communication, digital imaging and networking products that utilize market-leading SD technology. The SD standard is the number one choice for consumers and has earned more than 80 percent of the memory card market with its reliable interoperability and its easy-to-use format. Today, smart phones, tablets, drones, IoT devices, HDTVs, audio players, automotive systems, computers, digital cameras and digital video cameras feature SD interoperability. For more information about SDA or to join, please visit the Association’s website, https://www.sdcard.org.
SD Logos are trademarks licensed by SD-3C LLC.
PCI-SIG is the consortium that owns and manages PCI specifications as open industry standards. The organization defines industry standard I/O (input/output) specifications consistent with the needs of its members. Currently, PCI-SIG is comprised of nearly 800 industry-leading member companies. To learn more about PCI-SIG, and for a list of the Board of Directors, visit www.pcisig.com. PCI Express® is a registered trademark of PCI-SIG.
About NVM Express, Inc.
With more than 100 members, NVM Express is a non-profit organization focused on enabling broad ecosystem adoption of high performance and low latency non-volatile memory (NVM) storage through a standards-based approach. The organization offers an open collection of NVM Express (NVMe™) specifications and information to fully expose the benefits of non-volatile memory in all types of computing environments from mobile to data center. NVMe-based specifications are designed from the ground up to deliver high bandwidth and low latency storage access for current and future NVM technologies. For more information, visit http://www.nvmexpress.org.
PCIe® -PCI Express, is a standard developed by PCI-SIG® and PCIe® is a trademark owned by PCI-SIG.
NVMe™ - NVM ExpressTM, is a standard developed by NVM Express Inc. and NVMe™ is a trademark owned by NVM Express Inc.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CEST | Press release
Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo
Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi
LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CEST | Press release
LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom